Trial Profile

HNSALV Trial: Combining Immunotherapy with Salvage Surgery and IORT for Treatment of Persistent/Recurrent Head and Neck Cancers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Pharyngeal neoplasms; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Acronyms HNSALV

Most Recent Events

17 Mar 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
01 Mar 2022 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Feb 2022 to 1 May 2022.
01 Mar 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com